Comparison · NCT01767909-sae
Insulin (Humulin® R U-100) vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Insulin (Humulin® R U-100) vs Placebo: serious adverse events. Trial comparisons, record NCT01767909-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01767909-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.149 | 0.0962 | 0.223 | wilson | |
| Risk in group 2 | 0.084 | 0.0463 | 0.148 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0647 | -0.0179 | 0.148 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.77 | 0.853 | 3.67 | log | |
| Odds ratio, group 1 over group 2 | 1.9 | 0.84 | 4.32 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Insulin (Humulin® R U-100) than on Placebo | 15.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Insulin (Humulin® R U-100) | 50% of participants received 20 IU BID intranasal insulin (Humulin® R U-100) twice daily for a total of 40 IU daily for 12 months, followed by a 6-month open label period. | 18 | 121 | EG000 |
| Group 2 | Placebo | 50% of participants received placebo treatment twice daily for 12 months followed by a 6-month open label period where all participants received 20 IU BID intranasal insulin (Humulin® R U-100) twice daily (total of 40 IU daily). | 10 | 119 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Event Table represents data collected over a period of 12 months (blinded phase).
Source ClinicalTrials.gov
Trial
- Title
- The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
- NCT number
- NCT01767909
- Phases
- PHASE2, PHASE3
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Insulin (Humulin® R U-100), Placebo
- Lead sponsor
- University of Southern California
- Results first posted
- 2020-05-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01767909?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01767909-sae